AbolerIS Pharma
PrivateLast Round
Series A
Sep 18, 2023
Total Funding Raised
$32.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AbolerIS Pharma operates in Healthcare & Life Sciences and is based in Belgium. Its latest recorded funding round was a Series A round in September 2023.
AbolerIS Pharma is a biotechnology company that develops novel immunomodulatory antibodies to induce immune tolerance for treating inflammatory, autoimmune, and degenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AbolerIS Pharma Comparables
Compare AbolerIS Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Revolo Biotherapeutics | 76% | |
| NXI Therapeutics | 75% | |
| UCB | 74% |
For institutional investors. Book with your work email.
AbolerIS Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 18, 2023 | ||||
| Seed | Nov 4, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AbolerIS Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Series A |
| Newton Biocapital | Seed, Series A |
| Wallonie Entreprendre | Series A |
| Criteria Capital Risc | Series A |
| Sambrinvest | Series A |
| Sound Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 89% MoM.
- Oct 30, 2025
Philippe Alen appointed as the new Chief Business Officer.
For institutional investors. Book with your work email.
AbolerIS Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AbolerIS Pharma's valuation, stock price, and market status.
Is AbolerIS Pharma a public or private company?
AbolerIS Pharma is a private company.
What is the current stock price of AbolerIS Pharma?
AbolerIS Pharma is a private company, so its shares have no public market price. Caplight tracks AbolerIS Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AbolerIS Pharma worth (valuation)?
Valuation information for AbolerIS Pharma is not publicly available.
Can I buy AbolerIS Pharma stock?
AbolerIS Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AbolerIS Pharma's last funding round?
AbolerIS Pharma's most recent funding round was Series A on September 18, 2023.
Who are the main investors in AbolerIS Pharma?
Key investors in AbolerIS Pharma include Criteria Capital Risc.
Will AbolerIS Pharma IPO soon?
No public IPO plans have been announced for AbolerIS Pharma.
How can I track AbolerIS Pharma secondary market activity?
Caplight tracks bids, offers, and trades in AbolerIS Pharma's shares on secondary markets.